Obesity: Drugs
Commons · Question 73126 · Tabled 29 Aug 2025 · Department of Health and Social Care · Official record
Answered 9 Sep 2025
Question
Asked by Andrew Snowden
To ask the Secretary of State for Health and Social Care, what steps he has taken to ensure post-market surveillance of NHS-provided weight loss drugs to monitor their long-term effects in patients.
Answer
Answered by Ashley Dalton, 9 Sep 2025
The newest obesity medicines, liraglutide, under various brand names, semaglutide, under the brand name Wegovy, and tirzepatide, under the brand name Mounjaro, have only been licensed and recommended for use for the treatment of obesity over the last few ...